4 completed, 1 recruiting. 3 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
| Phase 3 | 1 | Completed 1 |
Follow Henning Bundgaard: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Copenhagen Baby Heart Study - Impact Clinical examination - Congenital Heart Disease | Recruiting | Henning Bundgaard | 35000 | 2018-11-01 | 2023-05-01 | |
| Beta 3 Agonist Treatment in Heart Failure-2 Mirabegron - Heart Failure With Reduced Ejection Fraction NYHA Class III-IV | Phase 2 / Phase 3 | Completed | Henning Bundgaard | 56 | 2017-01-23 | 2022-05-04 |
| Copenhagen Baby Heart Echocardiography, Blood analysis from umbilical cord blood, ECG - Congenital Heart Disease | Completed | Henning Bundgaard | 25000 | 2016-04-01 | 2020-10-19 | |
| Beta 3 Agonist Treatment in Heart Failure Mirabegron, Placebo - Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) | Phase 2 | Completed | Henning Bundgaard | 70 | 2013-09-30 | 2020-10-19 |
| Inhibition of the Renin Angiotensin System With Losartan in Patients With Hypertrophic Cardiomyopathy Losartan, Placebo - Hypertrophic Cardiomyopathy | Phase 2 | Completed | Henning Bundgaard | 130 | 2011-11-01 | 2014-07-09 |
Heart Defects, Congenital (2) · Cardiomyopathy, Hypertrophic (1) · Hypertrophy (1)
mirabegron (2) · Adrenergic beta-3 Receptor Agonists (1) · Losartan (1) · Restraint, Physical (1)
Denmark (4) · Australia (1)
PMID 25533774, PMID 26661322, PMID 27990717, PMID 30306423, PMID 31076139, PMID 33691309, PMID 34814190, PMID 35727876, PMID 35858538, PMID 37369832, PMID 37465966, PMID 37914855, PMID 38110921, PMID 38151605, PMID 38452283, PMID 39003423, PMID 40763039, PMID 41092104, PMID 41555067
2016 (1)